読み込み中
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
前日終値
$3.85
+$0.04 · +1.05%
日中の時刻はETです。市場データは遅延する場合があります。
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
日中レンジ
現在 $3.85
52週レンジ
現在 $3.85
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
23
割高
センチメント
47
まちまち
リスク
59
やや高いリスク
モメンタム
39
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
日中レンジ
現在 $3.85
52週レンジ
現在 $3.85
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（CHF） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | 497万 CHF | 703.8万 CHF | 1.9億 CHF | 933万 CHF |
| 売上原価 | 204.86万 CHF | 4750.4万 CHF | 4784.4万 CHF | 5074.9万 CHF | 5571.8万 CHF |
| 粗利益 | −204.86万 CHF | −4253.4万 CHF | −4080.6万 CHF | 1.39億 CHF | −4638.8万 CHF |
| 研究開発 | 4019.4万 CHF | 4860.4万 CHF | 4878.4万 CHF | 5074.9万 CHF | 5571.8万 CHF |
| 販売・一般管理 | 1487.1万 CHF | 1716.4万 CHF | 1899.5万 CHF | 2182.2万 CHF | 1690.6万 CHF |
| 営業費用 | 5089.42万 CHF | 1868.3万 CHF | 2030.2万 CHF | 7294.3万 CHF | 7274.9万 CHF |
| 受取利息 | 152.2万 CHF | 338.4万 CHF | 427.9万 CHF | 119.57万 CHF | 10.83万 CHF |
| 支払利息 | 1.8万 CHF | 2.5万 CHF | 4.9万 CHF | 64.81万 CHF | 60.81万 CHF |
| 減価償却費と償却費 | 214.4万 CHF | 236.9万 CHF | 242万 CHF | 238.8万 CHF | 256.5万 CHF |
| 営業利益 | −5812.4万 CHF | −6121.7万 CHF | −6110.8万 CHF | 1.17億 CHF | −6341.8万 CHF |
| 純利益 | −6165.1万 CHF | −5404.3万 CHF | −6198.4万 CHF | 1.18億 CHF | −6378.5万 CHF |
会社概要が更新されました 2026年10月10日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$21.00
上昇余地（445.45%）AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
